The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Kinnate Biopharma Inc. | COM | 49705R105 | 22,921,794 | 9,671,643 | SH | SOLE | 9,671,643 | 0 | 0 | ||
Kura Oncology, Inc. | COM | 50127T109 | 26,602,238 | 1,849,947 | SH | SOLE | 1,849,947 | 0 | 0 | ||
Lyell Immunopharma, Inc. | COM | 55083R104 | 16,150,500 | 8,325,000 | SH | SOLE | 8,325,000 | 0 | 0 | ||
Pharvaris N.V. | COM | N69605108 | 113,289,518 | 4,038,842 | SH | SOLE | 4,038,842 | 0 | 0 | ||
Syndax Pharmaceuticals, Inc. | COM | 87164F105 | 18,908,750 | 875,000 | SH | SOLE | 875,000 | 0 | 0 |